A biology-driven approach to drug discovery excellence Delivering Next Generation Medicines NGM Bio is a research-driven, clinical-stage biopharmaceutical company that has generated a promising pipeline of therapeutics addressing cardio-metabolic and liver diseases. Our deep expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving the development of transformational medicines that dramatically improve human health. Learn more. June 8, 2016 NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH May 23, 2016 SF Business Times – Another Genentech? These are the most likely companies November 9, 2015 NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD’s The Liver Meeting® 2015 © 2016 NGM BiopharmaceuticalsWebsite Design: Hane Chow, Inc.

Targeted Drug Discovery NGM’s most advanced drug discovery efforts aim to find new medicines to treat cardio-metabolic diseases, liver diseases and cancer, the latter by developing therapeutics in a field known as immuno-oncology or cancer immunotherapy. Two common threads run through these therapeutic areas. First, many patients are severely or fatally impacted by these diseases each year because optimal therapeutic options are lacking. Second, a comprehensive understanding of the underlying biology that initiates and drives these diseases is still emerging. At NGM, we believe interrogating these biologies can lead to the discovery and development of new medicines that will redirect the course of human disease and significantly improve the lives of patients. While industry research efforts typically pursue targets or pathways with ostensible links to a disease, NGM focuses solely on the most powerful biological mechanisms that we believe drive disease pathophysiology. Thereafter, we develop proprietary biologics to treat the diseases through those mechanisms. We seek to identify or elucidate novel targets or pathways, while inventing novel ways of modulating well-known biological targets that may potentiate previously unavailable treatment options. All of NGM’s announced clinical candidates are first-in-class therapies and several are modulating targets or pathways that were first identified by NGM. © 2016 NGM BiopharmaceuticalsAll rights reservedWebsite Design: Hane Chow, Inc.